Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ryman HealthcareRHCGF +0.75%42 Cash-to-Debt is 0.01 as of Mar. 2026, which is at its 10-year median of 0.01. GuruFocus rates RHCGF with a GF Score™ of 42/100 and a GF Value™ of $3.90 (Significantly Undervalued). Among 673 Healthcare Providers & Services companies, Ryman Healthcare ranks worse than 98.22% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ryman Healthcare's cash to debt ratio for the quarter that ended in Mar. 2026 was 0.01.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Ryman Healthcarecouldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Ryman Healthcare's Cash-to-Debt or its related term are showing as below:
RHCGF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 0.02
Current: 0.01
During the past 13 years, Ryman Healthcare's highest Cash to Debt Ratio was 0.02. The lowest was 0.01. And the median was 0.01.
RHCGF's Cash-to-Debt is ranked worse than 98.22% of 673
companies
in the Healthcare Providers & Services industry
Industry Median: 0.78
vs RHCGF: 0.01
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Ryman Healthcare Cash-to-Debt Related Terms
Ryman Healthcare Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Ryman Healthcare's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Care Facilities subindustry, Ryman Healthcare's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryman Healthcare Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ryman Healthcare's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Ryman Healthcare's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryman Healthcare (RHCGF) has a Cash-to-Debt of 0.01 as of Mar. 2026. This is near median its historical median of 0.01. Over the past decade, Ryman Healthcare's Cash-to-Debt has ranged from 0.01 to 0.02. According to the industry distribution chart, Ryman Healthcare ranks #661 out of 673 companies in the Healthcare Providers & Services industry, placing it in the top 98.2%.
Is Ryman Healthcare's Cash-to-Debt too high?
Ryman Healthcare's current Cash-to-Debt of 0.01 is near median its 10-year median of 0.01. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.02. The Healthcare Providers & Services industry median Cash-to-Debt is 0.78. Ryman Healthcare's value of 0.01 is 98.7% below this industry median. Based on the distribution chart, Ryman Healthcare ranks #661 out of 673 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Ryman Healthcare has a GF Score™ of 42/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ryman Healthcare's Cash-to-Debt compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Ryman Healthcare ranks #661 out of 673 companies for Cash-to-Debt. This places Ryman Healthcare in the lower half of its industry. The industry median Cash-to-Debt is 0.78. Ryman Healthcare's value of 0.01 is 98.7% below this benchmark. Historically, Ryman Healthcare's own Cash-to-Debt has ranged from 0.01 to 0.02 over the past decade. While the company's 10-year median is 0.01 vs. the industry median of 0.78, Ryman Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.78, based on 673 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ryman Healthcare's current Cash-to-Debt of 0.01 is 98.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ryman Healthcare's current Cash-to-Debt is 0.01, which is near median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryman Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Ryman Healthcare (RHCGF) is currently considered Significantly Undervalued. The stock's GF Value™ is $3.90, compared to a current price of $1.12 — trading 71.3% below its estimated fair value. The current Cash-to-Debt is 0.01, which is near median its 10-year median of 0.01 and 98.7% below the Healthcare Providers & Services industry median of 0.78. Ryman Healthcare's overall GF Score™ is 42/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Ryman Healthcare (RHCGF), the current Cash-to-Debt is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ryman Healthcare (RHCGF) Overvalued in 2026?
Based on GuruFocus' analysis, Ryman Healthcare stock appears to be undervalued.
The current stock price of $1.12 is trading 71.3% below its estimated GF Value™ of $3.90.
GuruFocus considers Ryman Healthcare to be Significantly Undervalued.
Key valuation signals for RHCGF:
Cash-to-Debt: 0.01 (near median its 10-year median of 0.01)
GF Value™: $3.90 vs. price of $1.12 (71.3% below fair value)
Industry Position: 98.7% below the Healthcare Providers & Services median (#661 of 673)
No single metric tells the full story. See the RHCGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ryman Healthcare Ltd is a retirement living and aged care provider operating in New Zealand and Australia. It owns and operates integrated retirement villages through its trading subsidiaries, which operate in the aged care and retirement living sector in New Zealand and Australia. The Group operates in a single industry: the provision of integrated retirement living and aged care for older people in New Zealand and Australia. The majority of revenue is derived from Care and village fees, which relate to the provision of accommodation, care and related services to aged care residents and retirement living residents.
42GF Score
Get the complete analysis for RHCGF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RHCGF has been successfully added to your 
